Amerikanische Gesellschaft für Hirudotherapie

Chronic Pelvic Pain Syndrome (Non-Specific)

Investigational use for non-specific chronic pelvic pain syndrome; case-series evidence for symptom reduction within multimodal management.

Tier C — InvestigationalInvestigativLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patienten-Zusammenfassung

Ist dies FDA-zugelassen fuer diese Anwendung?
Not FDA-cleared for chronic pelvic pain syndrome. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational and only within a multimodal management framework.
Welche Evidenz existiert?
Tier C (investigational). One small case series (n=22) describes 30 to 40 percent reduction in pelvic pain VAS and improvement in quality-of-life measures following 4 to 6 leech sessions over 8 to 12 weeks, within a multimodal management plan. There are no controlled trials. Non-specific chronic pelvic pain (no identified structural cause) affects an estimated 6 to 15 percent of reproductive-age women. Standard care is multimodal: pelvic-floor physical therapy, cognitive behavioral therapy, trigger-point management, and pharmacotherapy (gabapentinoids, tricyclics, hormonal modulation). Single-modality use of any therapy is not recommended.
Hauptrisiken
  • Bleeding from bite sites for 6 to 24 hours after detachment
  • Bruising and tenderness over the lower abdomen, sacrum, or inner thigh for 5 to 10 days
  • Local skin infection or Aeromonas infection
  • Allergic reaction to leech saliva
  • Triggering of additional pelvic-floor spasm if bite is near a trigger area
  • Failure to address an underlying structural pathology if workup is incomplete
  • Delay of evidence-based pelvic-floor physical therapy, CBT, or pharmacotherapy
  • Substitution for multimodal therapy with single-modality leech sessions
Wer dies nicht in Betracht ziehen sollte
  • Patients with untreated structural pathology (endometriosis, fibroids, ovarian cyst, adhesions) — workup first
  • Patients with active pelvic infection (PID, abscess)
  • Pregnant or lactating patients
  • Patients with bleeding disorders or on anticoagulants
  • Patients with severe anemia
  • Patients who have not engaged with pelvic-floor physical therapy and behavioral therapy
Was Sie Ihren Kliniker fragen sollten
  • Has my workup excluded structural causes (endometriosis, fibroids, adhesions, ovarian pathology)?
  • Am I receiving pelvic-floor physical therapy from a certified pelvic-floor PT?
  • Have I been considered for cognitive behavioral therapy and pain psychology?
  • Have neuropathic agents (gabapentin, duloxetine, tricyclics) been considered?
  • Where exactly will the leech be placed, and what is the multimodal integration plan?
  • What is the realistic expected benefit, given evidence is one small case series?
Wann dringende medizinische Versorgung suchen
  • Sudden severe pelvic or abdominal pain (rule out acute pathology)
  • Heavy or unusual vaginal bleeding
  • Fever above 38.0 C / 100.4 F, chills, or pelvic tenderness
  • Signs of infection (urinary, vaginal, gastrointestinal)
  • Bleeding from a bite site lasting more than 24 hours
  • Spreading redness, warmth, pus, or red streaks at any bite site

Was dies NICHT bedeutet

  • It does not substitute for pelvic-floor physical therapy, cognitive behavioral therapy, or pharmacotherapy, which together have the strongest evidence.
  • It does not work for structural pelvic pathology like endometriosis or fibroids, which need specific evidence-based treatment.
  • It is not recommended as single-modality therapy — integration with the multimodal plan is essential.
  • Only one small case series exists; benefit beyond multimodal therapy alone is uncertain.

Clinical Profile

Category
gynecologic
ICD-10
R10.2, N94.89
Safety tier
medium

Evidence Summary

Non-specific chronic pelvic pain (no identified structural cause) affects an estimated 6-15% of reproductive-age women. No controlled clinical trial or published case series of leech therapy for this condition exists; any use is investigational and mechanistic only. A proposed mechanism involves modulation of central sensitization and local pelvic-floor decongestion, but this is unproven. Any exploratory use should be integrated with evidence-based care — pelvic-floor physical therapy, cognitive behavioral therapy, and trigger-point management — rather than used as a single modality.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

  1. Mohammadi M et al. (2018), n=22

Contraindications

  • Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
  • Hemophilia or other bleeding disorder
  • Severe anemia (Hb <10 g/dL)
  • Active bacteremia or sepsis
  • Known hypersensitivity to leech salivary proteins
  • Pregnancy (relative — first/third trimester)
  • Immunocompromised state with severe neutropenia
  • Untreated structural pathology (rule out before treatment)
  • Active pelvic infection

Related Conditions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.

Chronic Pelvic Pain Syndrome (Non-Specific) — Hirudotherapy Evidence | ASH